MRC1 and neoplasm: As soon as palpable tumors became visible, LLC‐OVA tumor‐bearing mice were treated with 205 μg (∼13 nmol) of anti‐MMR Nb‐IMDQ (corresponding to 5.0 μg IMDQ) and a fivefold molar excess of bivalent anti‐MMR Nb, according to the schedule depicted in Figure8A.